Free Trial
NYSEAMERICAN:CVRS

Corindus Vascular Robotics (CVRS) Stock Price, News & Analysis

Corindus Vascular Robotics logo
$4.27 0.00 (0.00%)
As of 11/27/2019

About Corindus Vascular Robotics Stock (NYSEAMERICAN:CVRS)

Key Stats

Today's Range
$4.27
$4.27
50-Day Range
$4.27
$4.27
52-Week Range
$0.78
$4.40
Volume
N/A
Average Volume
1.99 million shs
Market Capitalization
$891.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Corindus Vascular Robotics, Inc. designs, manufactures, and sells robotic-assisted systems for use in interventional vascular procedures in the United States and internationally. The company offers CorPath system, a medical device with robotic-assisted precision for coronary and peripheral interventional procedures. Its CorPath system allows the physician to perform procedures with a control console located within an interventional cockpit; and CorPath GRX system enables the precise robotic-assisted control of guide catheters, guidewires, and balloon/stent devices from the safety of a radiation-shielded interventional cockpit. The company sells its products through direct sales force, as well as through distributor and partnership relationships. It serves vascular, coronary, peripheral vascular, neurointerventional, and structural heart markets. Corindus Vascular Robotics, Inc. is headquartered in Waltham, Massachusetts.

Receive CVRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corindus Vascular Robotics and its competitors with MarketBeat's FREE daily newsletter.

CVRS Stock News Headlines

Corindus Vascular Robotics, Inc.
HealthCor Partners Fund II, L.P.'s Net Worth
The Hidden Energy Source Backed by Billionaires
Why Billionaires Have Set Their Sights on the Utah Desert Something strange is happening near the Wah Wah Mountains in Utah. Bezos, Buffett, and Gates are getting involved. But few Americans know why this remote patch of land is suddenly worth billions. One of our own insiders even filed a FOIA request in Washington to get to get the truth.
Robotics & AI
See More Headlines

CVRS Stock Analysis - Frequently Asked Questions

Corindus Vascular Robotics' stock was trading at $4.27 at the beginning of 2025. Since then, CVRS stock has increased by 0.0% and is now trading at $4.27.
View the best growth stocks for 2025 here
.

Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS) announced its quarterly earnings data on Tuesday, August, 7th. The medical equipment provider reported ($0.06) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by $0.01. The medical equipment provider had revenue of $1.67 million for the quarter, compared to analyst estimates of $3 million.

Shares of CVRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Corindus Vascular Robotics investors own include Amarin (AMRN), TransEnterix (TRXDW), Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Helios and Matheson Analytics (HMNY) and Meta Platforms (META).

Company Calendar

Last Earnings
8/07/2018
Today
5/24/2025

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Sector
Medical
Industry
Medical Appliances & Equipment
Sub-Industry
Medical Equipment
Current Symbol
NYSEAMERICAN:CVRS
Previous Symbol
NYSEMKT:CVRS
CIK
N/A
Fax
N/A
Employees
90
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$891.08 million
Optionable
Not Optionable
Beta
N/A
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NYSEAMERICAN:CVRS) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners